Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.

Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, Xu CF, Neubert TA, Skoda RC, Hubbard SR, Silvennoinen O.

Nat Struct Mol Biol. 2011 Aug 14;18(9):971-6. doi: 10.1038/nsmb.2099.

2.

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.

Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR.

Nat Struct Mol Biol. 2012 Aug;19(8):754-9. doi: 10.1038/nsmb.2348. Epub 2012 Jul 22.

3.

New insights into the structure and function of the pseudokinase domain in JAK2.

Silvennoinen O, Ungureanu D, Niranjan Y, Hammaren H, Bandaranayake R, Hubbard SR.

Biochem Soc Trans. 2013 Aug;41(4):1002-7. doi: 10.1042/BST20130005. Review.

PMID:
23863170
5.

Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.

Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O.

PLoS One. 2011 Apr 18;6(4):e18522. doi: 10.1371/journal.pone.0018522.

6.

Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

Min X, Ungureanu D, Maxwell S, Hammarén H, Thibault S, Hillert EK, Ayres M, Greenfield B, Eksterowicz J, Gabel C, Walker N, Silvennoinen O, Wang Z.

J Biol Chem. 2015 Nov 6;290(45):27261-70. doi: 10.1074/jbc.M115.672048. Epub 2015 Sep 10.

PMID:
26359499
7.

Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.

Shan Y, Gnanasambandan K, Ungureanu D, Kim ET, Hammarén H, Yamashita K, Silvennoinen O, Shaw DE, Hubbard SR.

Nat Struct Mol Biol. 2014 Jul;21(7):579-84. doi: 10.1038/nsmb.2849. Epub 2014 Jun 11.

8.

Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling.

Robertson SA, Koleva RI, Argetsinger LS, Carter-Su C, Marto JA, Feener EP, Myers MG Jr.

Mol Cell Biol. 2009 Jun;29(12):3367-78. doi: 10.1128/MCB.00278-09. Epub 2009 Apr 13.

9.

ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Hammarén HM, Ungureanu D, Grisouard J, Skoda RC, Hubbard SR, Silvennoinen O.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4642-7. doi: 10.1073/pnas.1423201112. Epub 2015 Mar 30.

10.

Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.

Varghese LN, Ungureanu D, Liau NP, Young SN, Laktyushin A, Hammaren H, Lucet IS, Nicola NA, Silvennoinen O, Babon JJ, Murphy JM.

Biochem J. 2014 Mar 1;458(2):395-405. doi: 10.1042/BJ20131516.

11.

Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.

Wan X, Ma Y, McClendon CL, Huang LJ, Huang N.

PLoS Comput Biol. 2013 Apr;9(4):e1003022. doi: 10.1371/journal.pcbi.1003022. Epub 2013 Apr 4.

12.

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Saharinen P, Vihinen M, Silvennoinen O.

Mol Biol Cell. 2003 Apr;14(4):1448-59.

13.

Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.

Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MG Jr.

Mol Cell Biol. 2004 Jun;24(11):4968-78.

14.

A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation.

Zhao L, Dong H, Zhang CC, Kinch L, Osawa M, Iacovino M, Grishin NV, Kyba M, Huang LJ.

J Biol Chem. 2009 Sep 25;284(39):26988-98. doi: 10.1074/jbc.M109.011387. Epub 2009 Jul 28.

15.

Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.

Wan S, Coveney PV.

J Chem Inf Model. 2012 Nov 26;52(11):2992-3000. doi: 10.1021/ci300308g. Epub 2012 Oct 18.

PMID:
23033920
16.

The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains.

Sanz Sanz A, Niranjan Y, Hammarén H, Ungureanu D, Ruijtenbeek R, Touw IP, Silvennoinen O, Hilhorst R.

Biochim Biophys Acta. 2014 Oct;1844(10):1835-41. doi: 10.1016/j.bbapap.2014.07.003. Epub 2014 Aug 7.

PMID:
25107665
17.

JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.

Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN.

PLoS One. 2010 Jun 16;5(6):e11157. doi: 10.1371/journal.pone.0011157.

18.

A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).

Zhao L, Ma Y, Seemann J, Huang LJ.

Biochem J. 2010 Jan 27;426(1):91-8. doi: 10.1042/BJ20090615.

PMID:
19929856
19.

The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.

Li F, Guo HY, Wang M, Geng HL, Bian MR, Cao J, Chen C, Zeng LY, Wang XY, Wu QY.

Int J Biol Macromol. 2013 Sep;60:186-95. doi: 10.1016/j.ijbiomac.2013.05.029. Epub 2013 Jun 5.

PMID:
23748007
20.

Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.

Silvennoinen O, Hubbard SR.

Blood. 2015 May 28;125(22):3388-92. doi: 10.1182/blood-2015-01-621110. Epub 2015 Mar 30. Review.

Items per page

Supplemental Content

Write to the Help Desk